Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

Journal of Infectious Diseases

Volumn 177, Issue 1, 1998, Pages 40-47

  Marschner, Ian C ^a   Collier, Ann C ^b   Coombs, Robert W ^b   D'Aquila, Richard T ^b   DeGruttola, Victor ^b   Fischl, Margaret A ^b   Hammer, Scott M ^b   Hughes, Michael D ^b   Johnson, Victoria A ^b   Katzenstein, David A ^b   Richman, Douglas D ^b   Smeaton, Laura M ^b   Spector, Stephen A ^b   Saag, Michael S ^b  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NEVIRAPINE; SAQUINAVIR; SC 49483; UNCLASSIFIED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLASMA; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION;

EID: 17344364659     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513823     Document Type: Article

References (32)

1. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
2. Cao YC, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995;332:201-8.
3. Pantaleo G, Menzo S, Vaccarezzo M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995;332:209-16.
4. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
5. Coombs RW, Welles SL, Hooper C, et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-12.
6. Welles SL, Jackson BL, Yen-Lieberman B, et al. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and little or no prior zidovudine therapy. J Infect Dis 1996;174:696-703.
7. Phillips AN, Eron JJ, Bartlett JA, et al. HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-65.
8. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
9. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-31.
10. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1 infected adults. N Engl J Med 1996;335:1091-8.
11. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-38.
12. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-45.
13. Dolin R, Amato DA, Fischl MA, et al. Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. Arch Intern Med 1995;155:961-74.
14. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-7.
15. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-90.
16. Fischl MA, Richman DD, Saag M, et al. The safety and antiviral activity of combination therapy with zidovudine, zalcitabine and two doses of interferon α-2a in patients with HIV infection (ACTG study 197). J Acquired Immune Defic Syndr Hum Retrovirol 1997 (in press).
17. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996;334:1011-7.
18. D'Aquila RT, Hughes MD, Johnson VA, et al. A randomized double-blind placebo-controlled trial of nevirapine, zidovudine, and didanosine versus zidovudine and didanosine in patients with human immunodeficiency virus type 1 infection. Ann Intern Med 1996;124:1019-31.
19. Calvelli T, Denny TN, Paxton H, Gelman R, Kagan J. Guideline for flow cytometric immunophenotyping: a report from the National Institute of Allergy and Infectious Diseases, Division of AIDS. Cytometry 1993;14:702-15.
20. Gelman R, Cheng SC, Kidd P, Waxdal M, Kagan J. Assessment of effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DAIDS flow cytometry quality assessment program. Clin Immunol Immunopathol 1993;66:150-62.
21. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
22. Lin HJ, Myers LE, Yen-Lieberman B, et al. Multicenter evaluation of quantitative methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:552-62.
23. Japour, AJ, Fiscus S, Arduino J, Mayers D, Reichelderfer P, Kuritzkes DR. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994;32:2291-4.
24. Kleinbaum DG. Survival analysis. New York: Springer, 1996.
25. Paxton WB, Coombs RW, McElrath MJ, et al. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with ≥400 CD4 lymphocytes: implications for applying measurements to individual patients. J Infect Dis 1997;175:247-54.
26. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995;267:483-9.
27. Henrard J, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
28. Loveday C, Hill A. Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995;345:790-1.
29. + cell count in HIV disease: implications for clinical trial design and analysis. Antiviral Res 1996;29:83-6.
30. Pitt J, Brambilla D, Reichelderfer P, et al. Maternal immunologic and virologic risk factors for infant human immunodeficiency virus type 1 infection: findings from the women and infants transmission study. J Infect Dis 1997;175:567-75.
31. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. J Infect Dis 1997;175:1029-38.
32. D'Aquila RT, Johnson VA, Welles SL, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-8.